From Bio­gen’s buy side to biotech CEO: Josh Man­del-Brehm joins the Po­laris fam­i­ly as a se­r­i­al en­tre­pre­neur in the mak­ing

Last Fri­day, Josh Man­del-Brehm wrapped a 4-year stint at Bio­gen, clos­ing out a chap­ter of his life that end­ed with a run as head of busi­ness de­vel­op­ment for the big biotech. This week he start­ed a new chap­ter as en­tre­pre­neur-in-res­i­dence at Po­laris Part­ners, one of the busiest ven­ture play­ers in biotech. Next stop: CEO of a stealth biotech that’s cur­rent­ly craft­ing a pipeline ahead of the Se­ries A now be­ing put to­geth­er, ex­pect­ed to ar­rive lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.